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Repetitive transcranial magnetic stimulation (rTMS) has been reported to be a new treatment option 
for treatment-resistant depression.  In Japan,  there has been limited research into its feasibility,  eﬃ-
cacy,  and tolerability.  We have launched a trial of rTMS for treating medication-resistant major 
depressive disorder and bipolar depression.  We are investigating low-frequency rTMS to the right 
dorsolateral prefrontal cortex and traditional high-frequency rTMS to the left dorsolateral prefrontal 
cortex,  in 20 patients.  The primary outcome of the study is the treatment completion rate.  This study 
will provide new data on the usefulness of rTMS for treatment-resistant depression in Japan.
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M ajor depressive disorder (MDD) and bipolar disorder (BD) are prevalent psychiatric condi-
tions.  They account for almost a half of the disability-
adjusted life-years caused by mental and substance use 
disorders,  and are one of the leading causes of disease 
burden [1].  In Japan,  epidemiologic studies have 
revealed that the 12-month and lifetime prevalence of 
mood disorders (including BD) are 2.3  and 6.5 ,  
respectively [2].
　 Treatment-resistant major depressive episode 
(TR-MDE) is a common issue in clinical practice [3].  
Recently,  repetitive transcranial magnetic stimulation 
(rTMS) has been reported to be an eﬀective and well-
tolerated antidepressant treatment for TR-MDE [4-8].  
rTMS is a noninvasive technique stimulating the 
cerebral cortex,  altering cortical and subcortical 
function,  and has been reported to have therapeutic 
eﬀects in several neuropsychiatric disorders,  includ-
ing mood disorders [9].  rTMS for the treatment of 
MDD has been approved in North America,  Latin 
America,  Europe,  Australia,  New Zealand,  Israel,  
and Korea,  among other countries.  Typically,  one of 
two equally eﬀective typical stimulation protocols are 
used [10]; traditional high-frequency rTMS to the left 
dorsolateral prefrontal cortex (HF-LDLPFC),  as 
approved by the U.S. Food and Drug Administration;  
or an experimental low-frequency rTMS to the right 
DLPFC (LF-RDLPFC),  which has fewer side eﬀects.  
The eﬀect size for rTMS antidepressant eﬃcacy is at 
least comparable to those of antidepressant medica-
tions,  even though previous studies included only 
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treatment-resistant or treatment-intolerant depressed 
patients [11].  In contrast to major depressive episode 
(MDE) in MDD,  on which the majority of published 
rTMS studies have focused,  there have been few 
studies investigating the eﬀect of rTMS on MDE in 
BD [12-15].
　 In Japan,  no rTMS device for treatment use has 
been approved by the Ministry of Health,  Labour and 
Welfare,  which has resulted in its oﬀ-label use.  
Therefore,  there have been only limited data available 
on the eﬃcacy and tolerability of rTMS for the treat-
ment of MDE in Japan [16-21].  To date,  there have 
been no reports of the feasibility and eﬃcacy of the 
rTMS parameters used in the present study in Japan 
and other parts of Asia.
　 This study will examine the feasibility and prelimi-
nary eﬃcacy of rTMS for TR-MDE in Japan.  The 
primary outcome of the study is treatment completion 
rate.  Secondary outcome measures include assessment 
of the severity of depression and mania.
Endpoints
　 The primary outcome of this study is the treatment 
completion rate.  We use the following criteria for 
terminating the intervention: patientʼs request to ter-
minate treatment,  the occurrence of a serious adverse 
event,  detection of pregnancy,  and a physicianʼs deci-
sion based on risk or other reasons.  Treatment com-
pletion is deﬁned as the patient undergoing prescribed 
sessions without termination of treatment.  Secondary 
outcome measures include scores on the HAM-D 
17-item version [22],  the Montgomery-Åsberg 
Depression Rating Scale (MADRS) [23],  the Beck 
Depression Inventory-II (BDI-II) [24],  the Young 
Manic Rating Scale (YMRS) [25],  and the Frequency,  
Intensity,  and Burden of Side Eﬀects Rating scale 
(FIBSER) [26].  These parameters are assessed at 
baseline (T1),  2 (T2),  4 (T3),  and 24 weeks (T6).  At 
8 (T4) and 12 weeks (T5),  only the BDI-II is adminis-
tered.  Fig.  1 shows an overview of the study design.
　 HAM-D.  The HAM-D is the most widely used 
observer-rated scale to assess level of depression in 
clinical research.  The original version,  developed in 
1960,  contains 17 items [22].  We use the Japanese 
version of the Structured Interview Guide for 
Combined Rating of HAM-D and the Inventory of 
Depressive Symptomatology-Clinician Rated (IDS-C),  
which have been used in the Sequenced Treatment 
Alternatives to Relieve Depression (STAR＊D) study 
[27].
　 MADRS.  The MADRS is a common observer-
rated 10-item scale to assess level of depression [23].  
We use the Japanese version of the MADRS using a 
structured interview guide for MADRS (SIGMA),  
which has been shown to have good inter-rater reli-
ability [28].
　 BDI-II.  The BDI-II is a 21-item self-report 
instrument that assesses level of depression [24].  
Good reliability and validity have been reported for 
the Japanese version [29].
　 YMRS.  The YMRS is the most frequently used 
observer-rated 11-item scale to assess level of mania 
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Fig. 1　 Flow chart of the trial design.  MDE,  major depressive 
episode; MDD,  major depressive disorder ; BD,  bipolar 
disorder; HAM-D,  Hamilton Depression Rating Scale; EEG,  
electroencephalogram; SCID-I,  Structured Clinical Interview for 
DSM-IV-TR Axis I Disorders; MADRS,  Montgomery-Åsberg 
Depression Rating Scale; BDI-II,  Beck Depression Inventory-
II; YMRS,  Young Manic Rating Scale; FIBSER,  Frequency,  
Intensity,  and Burden of Side Effects Rating; LF,  low 
frequency; HF,  high frequency; DLPFC,  dorsolateral prefrontal 
cortex; RMT,  resting motor threshold.
or hypomania [25].  We use the Japanese version of 
YMRS-J,  with good inter-rater reliability [30].
　 FIBSER.  FIBSER was originally used in the 
STAR＊D study as a global rating scale for side 
eﬀects [26].  This is an observer-rated scale that 
consists of three domains evaluating the frequency,  
intensity,  and severity of side eﬀects.  The Japanese 
translation has not been validated by back-translation.
Eligibility Criteria
　 On April 1,  2014 we commenced a single-arm,  
prospective,  non-randomized,  non-comparative,  open-
label,  multicenter,  phase I and II trial.  Patient 
enrollment will ﬁnish on October 31,  2016.
　 The inclusion and exclusion criteria for the present 
study are listed in Table 1.  Written informed consent 
must be obtained from the patient before any screening 
or inclusion procedure.  This study is being conducted 
in compliance with the principles of the Declaration of 
Helsinki and the Ethical Guidelines for Medical and 
Health Research Involving Human Subjects.  The study 
has been approved by the Okayama University Graduate 
School of Medicine,  Dentistry and Pharmaceutical 
Sciences and the Okayama University Hospital,  Ethics 
Committee (approval numbers m22002 and 25-8,  
respectively).  This trial has been registered with the 
UMIN Clinical Trials Registry (registration number 
000013553).
　 The recruiting sites are Okayama University 
Hospital and Okayama Psychiatric Medical Center.  
Attending physicians (psychiatrists) screen patients for 
eligibility using a diagnosis of MDE according to the 
Diagnostic and Statistical Manual of Mental Disorders,  
Fourth Edition,  Text-Revision (DSM-IV-TR) [31],  
and assess the severity of their depression using the 
Hamilton Depression Rating Scale (HAM-D) [22].  
The attending physicians also check for abnormalities 
using electroencephalography,  and either brain mag-
netic resonance imaging or computed tomography.  
Researchers conﬁrm diagnoses using the Structured 
Clinical Interview for DSM-IV-TR Axis I Disorders 
(SCID-I) [32] and all eligibility criteria,  then seek 
written informed consent from eligible patients.
Treatment Methods
　 rTMS is administered using a Magstim Super 
Rapid stimulator® (Magstim Co.,  Whitland,  U.K.) and 
a hand-held,  focal 70-mm ﬁgure-of-eight coil.  Prior to 
the commencement of every rTMS session,  single-
pulse TMS is used to measure the resting motor 
threshold (RMT) for the abductor pollicis brevis using 
the standard method [33].  The stimulation area during 
the rTMS sessions is deﬁned by a point 5cm anterior 
to that required for maximum stimulation of the abduc-
tor pollicis brevis.
　 First,  researchers explain the risks and beneﬁts of 
both LF-RDLPFC and HF-LDLPFC to the patient 
and their physician.  Patients,  by default,  receive 
LF-RDLPFC treatment,  which has been suggested to 
be equally eﬀective and more tolerable compared with 
HF-LDLPFC treatment [10].  In addition,  as shown 
in Fig.  2,  the treatment time is shorter in LF-RDLPFC 
than HF-LDLPFC,  involving a lower burden on 
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Table 1　 Patient eligibility
Inclusion criteria
　　DSM-IV-TR diagnosis of major depressive disorder (MDD) or 
bipolar disorder (BD)
　　Hamilton Scale for Depression 17-item score: 14 or more
　　Medication resistance due to ineﬀectiveness or intolerable side 
eﬀects
　　　　Insuﬃcient clinical improvement of MDD from at least 2 
antidepressant trials
　　　　Insuﬃcient clinical improvement of BD from lithium or 
lamotrigine and atypical antipsychotic treatment
　　Capability to give informed consent
　　Aged 20 years old or more
Exclusion criteria
　　Other Axis I disorders
　　Axis II disorders
　　Seizure-inducing disease (brain tumor, head injury, etc.)
　　Neurologic disorder, organic brain disorder
　　History of seizure
　　Paroxysmal electroencephalogram abnormality
　　Pregnancy
　　Ferromagnetic material in head (except oral cavity)
　　Patients with a pacemaker
　　Active suicidal ideation
　　Stupor
　　Treatment with electroconvulsive therapy within the past 
month
　　Depression related to physical disease or drug use
　　Family members of researchers
　　Patients likely to change to another hospital within 6 months
　　Patients not appropriate for participation in the study as judged 
by the physician
　　Patients who do not understand Japanese
patients.  Therefore,  only when requested by the patient 
and their physician,  is HF-LDLPFC administered 
instead of LF-RDLPFC.  Fig.  2 shows the stimula-
tion protocol of LF-RDLPFC and HF-LDLPFC.  For 
LF-RDLPFC,  two 60-sec trains are applied at 1Hz 
and at 110  of RMT,  with a 120-sec inter-train inter-
val (total of 120 stimuli per session).  LF-RDLPFC 
stimulation sessions are performed daily on working 
days for 4 weeks.  For HF-LDLPFC,  75 4-sec trains 
are applied at 10Hz and at 120  of RMT with a 
26-sec inter-train interval (total of 3,000 stimuli per 
session).  During the ﬁrst week only,  treatment inten-
sity is reduced to 110  RMT for tolerability.  HF- 
LDLPFC stimulation sessions are performed daily on 
working days for 3 weeks.  In determining the proto-
col,  we reviewed prior trials and assessed the param-
eters with a favorable eﬃcacy-tolerability balance 
[34-39].
　 Throughout the study,  patients may receive their 
usual treatment,  including psychiatric drugs and psy-
chotherapy,  but not electroconvulsive therapy or 
transcranial direct current stimulation.
Statistical Consideration
　 We will report baseline characteristics and results 
for qualitative analysis.  To evaluate preliminary eﬃ-
cacy,  assuming that 30  of patients remit,  another 
30  respond,  the other 30  would not respond or get 
worse,  at least 15 patients will be needed to ensure 
each category includes at least 5 patients [8,  40].  We 
determined that a sample of 20 patients is needed,  
taking into account dispersion.  We considered that the 
sample size would be enough to evaluate the feasibility 
as the primary outcome of the present study.
　 This study will show the feasibility and preliminary 
eﬃcacy of rTMS for TR-MDE in Japan.
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